Patients with advanced non-small cell lung cancer and uncommon EGFR mutations lived almost twice as long without disease progression with the targeted agent afatinib (Gilotrif) versus chemotherapy ...

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have ...

LUX-Lung 3 results highlighted at the official ASCO Press Conference: Afatinib* delays cancer progression significantly more than the best standard chemotherapy Ingelheim, Germany, 4 June 2012 ...

Afatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ...

Aims: To determine the maximum tolerated dose (MTD), safety and anti-tumor activity of afatinib combined with docetaxel in advanced cancer. Patients & methods: The MTD was determined from dose ...

Patients with advanced non–small cell lung cancer who harbored EGFR exon 19 deletions and who received first-line treatment with afatinib achieved significantly prolonged OS compared with ...

• Afatinib comes as a tablet which should be taken by mouth on an empty stomach preferably either two hours after a meal or one hour before a meal. • Never take afatinib tablets in smaller or ...

Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations ...

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have ...

Afatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ...